Diabetic Neuropathy Market Growth To Surge Owing To Increasing Adoption By (Use Applications) : Fact.MR

The diabetic neuropathy market refers to the global market for products and therapies that are used to treat and manage diabetic neuropathy, a type of nerve damage that can occur as a complication of diabetes. Diabetic neuropathy affects the nerves that control various functions of the body, including sensation, movement, and organ function. The diabetic neuropathy market is driven by the increasing prevalence of diabetes worldwide, which is a major risk factor for developing diabetic neuropathy. The market is also influenced by the growing awareness among patients and healthcare providers about the benefits of early detection and management of diabetic neuropathy, as well as the availability of new and effective treatments.

The market is segmented based on product type, treatment type, distribution channel, and geography. Based on product type, the market is divided into drugs, devices, and others. By treatment type, the market is segmented into pharmacological and non-pharmacological treatments. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Download Free Sample Copy of this Report –

Key Segments of Diabetic Neuropathy Industry Research

  • By Disorder :
    • Peripheral Neuropathy
    • Autonomic Neuropathy
    • Proximal Neuropathy
    • Focal Neuropathy
  • By Treatment :
    • Drugs
      • Analgesic
        • Topical
          • Capsaicin
          • Others
        • Opioid
          • Morphine
          • Others
        • NSAIDs
          • Ibuprofen
          • Naproxen
          • Others
        • Antidepressants
          • TCAs
            • Amitriptyline
            • Imipramine
            • Others
          • SNRIs
            • Duloxetine
            • Others
          • SSRIs
            • Citalopram
            • Paroxetine
            • Others
        • Anticonvulsant Drugs
          • Gabapentin
          • Pregabalin
          • Topiramate
          • Others
    • Other Drugs
    • Radiotherapy
      • Transcutaneous Electrical Nerve Stimulation (TENS)
      • Others
    • Physiotherapy
  • By Distribution Channel :
    • Hospitals
    • Clinics
    • Retail Pharmacies
    • Online Pharmacies
  • By Region :
    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Key Takeaways:

  • North America is expected to witness prominent usage of diabetic neuropathy drugs market during the forecast period.
  • Asia Pacific is expected to offer profitable opportunities and is anticipated to witness 1.5X of the growth during the forecast period. This is due to large patient pool and supportive government policies in the region.

Growth Drivers:

  • Healthcare providers are stepping up research and development in an effort to find a potential cure due to the lack of treatments that can reverse underlying nerve damage.
  • The market has seen significant growth as a result of drugs for the treatment of diabetic neuropathic pain receiving quick approval. For instance, Lyrica has received approval for the treatment of neuropathic pain in 130 nations.
  • Medical companies are being forced to invest a lot of money in drug development due to the Asia Pacific region’s inadequate healthcare system and lack of healthy eating habits.

Key Companies Profiled by Fact.MR

  • Pfizer Inc.
  • Arbor Pharmaceuticals
  • Janssen Global Services, LLC
  • Eli Lilly
  • Deposed, Inc.
  • NeuroMatrix, Inc.